Patient assistance services are available for MACUGEN®

Bausch and Lomb is committed to helping eligible patients obtain affordable treatments*

FREE personalized patient assistance available through the Focus on Access (FOA) program offering*:

  • Reimbursement counseling on MACUGEN®:
    • At your request, FOA counselors will see if the product prescribed is covered by your insurance
    • FOA counselors can also assist you with information concerning the prior authorization process, claim denials, and the appeals process
  • Eligibility for patient assistance for those without insurance coverage*
    • You may be eligible if you do not have insurance coverage
  • Eligibility to receive the product at no cost*
    • You may be eligible based on:
      • Lack of access to the product prescribed
      • Documentation of household income
      • Proof of US residency

*Terms and Conditions Apply. Your doctor can refer you to the Focus on Access program to determine your eligibility for patient assistance.

For information on Reimbursement and Patient Assistance Services, Call the FOCUS ON ACCESS Hotline, (866) 272-8838 (Monday-Friday, 9 AM to 5 PM EST).

FAQs About Coverage and Reimbursement*

What if you have insurance but the product is not covered?
  • If a claim is denied, an FOA counselor will assist you with information concerning the claim-appeal process
  • You may also be considered for the Patient Assistance Program
What if you are still without insurance after 1 year?
  • Continued assistance may be provided after you reapply to the program and you meet the pre-established eligibility criteria*
  • In order to be considered for continued assistance, you must submit an application every 12 months*
How can I get started?
  • You need to fill out the Patient Information section of the FOA enrollment form
  • Your doctor will provide you with this form
  • The form will instruct you what information you need to supply
  • Submit your filled out enrollment form with the necessary documents by mail or fax to:

    PO Box 220662
    Charlotte, NC 28222-0662
    FAX: (866) 272-8839

Please note: Faxed enrollment forms are acceptable

*Terms and Conditions Apply. Your doctor can refer you to the Focus on Access program to determine your eligibility for patient assistance.

UPDATE: Click here to order samples for your practice.


MACUGEN® (pegaptanib sodium injection) is approved to treat wet age-related macular degeneration, a condition that could affect your vision due to leaking blood vessels in your eye.

Important Safety Information

  • You should not receive MACUGEN® (pegaptanib sodium injection) if you have an infection in or around your eye or if you are allergic to pegaptanib sodium or any of the other ingredients. Contact your doctor immediately if you have unusual swelling, rash, or difficulty breathing after having a MACUGEN® injection.
  • In the days following MACUGEN® administration, you may be at risk for the development of endophthalmitis (inflammation of the inner coats of the eye due to an infection). If the eye becomes red, sensitive to light, painful, or develops a change in vision, contact your doctor immediately so you can be treated early if an infection occurs.
  • MACUGEN® can increase eye pressure within 30 minutes after it is injected into your eye. Your doctor may do some extra tests after your injection to make sure there are no complications or problems.
  • Serious side effects related to the injection procedure have been seen in patients receiving eye injections such as MACUGEN®. These include endophthalmitis, a separation in the retina referred to as retinal detachment, and cataract. Less than 1% of injections have caused a serious side effect.
  • The following side effects were reported by 10-40% of patients treated with MACUGEN® for up to two years in clinical studies: eye swelling, blurred vision, cataract, increased redness in the white of the eye, discharge from the eye, eye irritation, eye pain, high blood pressure, increased eye pressure, eye discomfort, visual disturbances, burning sensation, redness, light sensitivity, and vision loss.

You are encouraged to report side effects to the FDA. To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC, at 1‑800‑321‑4576 or FDA at 1‑800‑FDA‑1088 or

Please click here for full Prescribing Information for MACUGEN®.

Indication and Important Safety Information